Home/Pipeline/CUE-102

CUE-102

WT1‑positive tumors (booster)

Phase 1Active

Key Facts

Indication
WT1‑positive tumors (booster)
Phase
Phase 1
Status
Active
Company

About ImmunoScape

A Singapore biotech delivering next‑generation TCR‑T cell therapies via a seed‑and‑boost platform for solid‑tumor oncology.

View full company profile

Therapeutic Areas